<DOC>
	<DOCNO>NCT01026051</DOCNO>
	<brief_summary>The clinical trial evaluate multi-component active immunotherapy design stimulate immune reaction specific tumor associate antigens highly express melanoma</brief_summary>
	<brief_title>Safety , Immune Tumor Response Multi-component Immune Based Therapy ( MKC1106-MT ) Patients With Melanoma</brief_title>
	<detailed_description>The multi-component active immunotherapy , MKC1106-MT , consist 1 plasmid dose 2 peptide dos design stimulate immune reaction two tumor associate antigen ( Melan-A tyrosinase ) . The plasmid component administer Days 1 , 4 , 15 18 treatment cycle follow administration peptide Days 29 32 treatment cycle . All component administer separately non-diseased superficial inguinal lymph node ultrasound guidance</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis regional distant metastatic melanoma ( stage IIIB , IIIC , IV ) confine skin , subcutaneous tissue , lymph node refractory standard care , curative standard therapy exist ( Note : Subjects therapyna√Øve also eligible . ) Measurable disease Response Evaluation Criteria Solid Tumours ( RECIST ) 1.1 criterion ECOG performance status 0 1 Life expectancy &gt; = 3 month 18 year age old screen evaluation Subjects must able provide inform consent participation clinical trial protocolspecific clinical trial procedure perform Positive HLAA2 , precisely , expression A*0201 assess DNA type Tumor material prior biopsy/surgical resection available analysis expression melanoma specific antigens Adequate coagulation function evidence prothrombin time ( PT ) partial thromboplastin time ( PTT ) value within normal range Adequate bone marrow reserve evidence Absolute neutrophil count ( ANC ) &gt; = 1,000/mL ; platelet count &gt; = 75,000/mL Subjects must recover least baseline Grade 1 toxicity effect prior surgery , radiotherapy , therapy include limited chemotherapy Women childbearing potential well fertile men partner must agree use effective method contraception abstain sexual intercourse clinical trial 90 day follow last dose investigational drug . Subjects received local radiation therapy ( less onefourth bone marrow ) eligible . Subjects visceral metastasis ( Note : Subjects stable CNS metastasis fully treat CNS metastatic disease [ eg , radiation therapy ] eligible . ) Active infection require treatment Systemic inflammatory disease require chronic maintenance suppressive therapy Positive antibody test result HIV , hepatitis B , hepatitis C History allogeneic transplant Medical , sociological , psychological condition may compromise compliance participation may interfere interpretation result History receive immunosuppressive drug within 1 month dose Subjects lactate , pregnant , plan become pregnant within 3 month complete treatment Subjects receive investigational drug within 4 week dose Prior systemic radiation therapy ( onefourth bone marrow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Cancer Vaccine , Immunotherapy , Melanoma</keyword>
</DOC>